Topic

Articles

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Orchestrating a Life Sciences Ecosystem Where Everyone is an A-Player: Insights with Landmark Bio’s Ran Zheng

Dr. Mark Davies is an NHS Consultant and Director of 

. He has a background in marketing and advertising with an MBA and now works extensively with pharma teams supporting market access, brand strategy, commercial performance, partnership projects and real-world data projects (in partnership with Manchester University).

, a consultancy that provides medical affairs advice, resources, and capabilities. Paul has an MBA, a PhD, and is a Chartered Manager. He has 20 years of pharma industry experience, working in medical affairs, clinical development, and commercial roles.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.





Optimizing the Value of Real-World Evidence Projects

Vice President, Quality, Acceleron Pharma Inc.

Fellow, Institute for Inclusive Leadership, Professor of Practice (Retired), School of Business, Simmons University

Using the interview process to ensure high organizational standards.

How GxP Leaders Can Assess and Approach a Company’s Quality Culture

With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.

Startup Launch Guide: Avoiding 10 Common Pain Points 

Dr. Bethany Valente is the founder and managing partner of 

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.










Making the Most of the Rising Biopharma M&As

Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.

Purposeful Partnerships for Post-COVID Era

Amgen board member and serial CEO Fred Hassan talks about the three levers  Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Digital Transformation: A Journey, Not Just a Destination

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternative

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.

Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs

Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.

Strategy